Transoral robotic surgery (TORS)

PROCEDURE4 trials

Sponsors

University of Pennsylvania, M.D. Anderson Cancer Center, University of Chicago, Hospices Civils de Lyon

Conditions

HNSCCHPV-Related Squamous Cell CarcinomaObstructive Sleep ApneaOropharyngeal CancerSupraglottic Squamous Cell Carcinoma

Phase 2

Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

TerminatedNCT02225496

M.D. Anderson Cancer CenterOropharyngeal Cancer

Start: 2014-09-23End: 2017-12-08Updated: 2017-12-15

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

CompletedNCT03107182

University of ChicagoHNSCC, HPV-Related Squamous Cell Carcinoma

Start: 2017-06-27End: 2024-09-06Updated: 2025-05-06

Unknown Phase

Transoral Robotic Surgery (TORS) for Sleep Apnea

CompletedNCT01187160

University of PennsylvaniaObstructive Sleep Apnea

Start: 2009-10-31End: 2014-11-30Updated: 2016-08-22

Local Control After Robot-assisted Supraglottic Laryngectomy

CompletedNCT03357107

Hospices Civils de LyonSupraglottic Squamous Cell Carcinoma

Start: 2016-10-01End: 2017-02-28Updated: 2017-11-30

Related Papers

Circulating tumor HPV-DNA dynamics and neoadjuvant chemotherapy with or without nivolumab in viral-mediated oropharyngeal cancer.

Journal of Clinical Oncology2025-05-281 citations

Functional and survival outcomes in HPV positive oropharyngeal squamous cell cancer treated with response-adaptive de-escalation: A pooled analysis.

Journal of Clinical Oncology2025-05-28

Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV<sup>+</sup> Oropharyngeal Cancer

JAMA Oncology2024-06-0638 citations

Nivolumab-based induction chemoimmunotherapy and PD-L1 expression in locoregionally advanced HPV-associated oropharyngeal squamous cell carcinoma.

Journal of Clinical Oncology2022-06-012 citations

Swallowing and quality-of-life outcomes of response adaptive de-escalated therapy following nivolumab-based induction for HPV+ oropharyngeal cancer.

Journal of Clinical Oncology2022-06-011 citations

Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.

Journal of Clinical Oncology2021-05-2029 citations

Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial.

Journal of Clinical Oncology2021-05-206 citations